Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from Guggenheim

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a report released on Tuesday,Benzinga reports. They presently have a $60.00 target price on the stock. Guggenheim’s target price indicates a potential upside of 99.40% from the company’s current price.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Canaccord Genuity Group reduced their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday. BTIG Research reaffirmed a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research report on Monday, May 11th. Wedbush increased their target price on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Chardan Capital reissued a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.00.

Stoke Therapeutics Stock Up 1.8%

Shares of STOK traded up $0.53 during trading hours on Tuesday, hitting $30.09. The company had a trading volume of 78,162 shares, compared to its average volume of 745,661. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -10.77 and a beta of 1.20. The business has a fifty day moving average of $30.39 and a 200-day moving average of $32.00. Stoke Therapeutics has a 12 month low of $12.72 and a 12 month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. On average, equities analysts expect that Stoke Therapeutics will post -3.22 EPS for the current fiscal year.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of Stoke Therapeutics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $30.58, for a total value of $54,891.10. Following the completion of the sale, the insider owned 34,826 shares in the company, valued at $1,064,979.08. The trade was a 4.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the sale, the general counsel directly owned 18,086 shares of the company’s stock, valued at $541,675.70. This represents a 7.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in STOK. Hussman Strategic Advisors Inc. acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth $2,000,000. Baillie Gifford & Co. acquired a new position in Stoke Therapeutics in the fourth quarter valued at about $7,837,000. Candriam S.C.A. raised its stake in Stoke Therapeutics by 12.4% in the first quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock valued at $16,346,000 after purchasing an additional 55,330 shares in the last quarter. Janus Henderson Group PLC lifted its position in Stoke Therapeutics by 11.2% during the first quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock worth $52,456,000 after purchasing an additional 161,848 shares during the period. Finally, Privium Fund Management B.V. bought a new stake in Stoke Therapeutics during the fourth quarter worth about $1,746,000.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Chardan Capital reaffirmed its “Buy” rating and assigned a $35 price target, implying approximately 18% upside from the referenced $29.56 level. This provides a positive analyst catalyst for STOK. Benzinga analyst rating report
• Positive Sentiment: Second-quarter revenue was about $9.3 million, well above the $4.89 million consensus estimate. The result suggests stronger-than-anticipated revenue generation and may help offset concerns about the company’s ongoing cash burn. Zacks second-quarter earnings report
• Neutral Sentiment: Management provided business updates on zorevunersen, Stoke’s lead investigational RNA medicine and potential disease-modifying treatment for Dravet syndrome, including progress in its global development program. Investors are likely focused on clinical execution and future regulatory milestones. Stoke Therapeutics second-quarter business update
• Neutral Sentiment: Brokerages collectively rate STOK “Moderate Buy,” indicating generally favorable but not uniformly bullish expectations. Brokerage recommendation report
• Negative Sentiment: Stoke reported a quarterly loss of $0.93 per share, missing estimates of roughly $0.80–$0.82 and widening from a $0.40 loss a year earlier. Its negative net margin and return on equity underscore continued substantial operating losses. Stoke Therapeutics earnings report

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.